To require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.
TQL analysis
Not yet gradedThis bill has no published Quiet Ledger grade yet.
Legislative structure
Criterion breakdown8 criteria · max 90
No grade to break down.Actions (3)
| Date | Time | Action |
|---|---|---|
| 2017-07-28 | — | Referred to the House Committee on Energy and Commerce. |
| 2017-07-28 | — | Introduced in House |
| 2017-07-28 | — | Introduced in House |
The Quiet Ledger grades legislation on its content. A bill grade is analysis of the bill — not a grade of its sponsor or of any member who voted on it.